Osivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines Phase 2b study provides first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes OVX836 did not meet its pre-specified primary endpoint of 50% vaccine efficacy Results support development of OVX836 in combination …
Archives de l’auteur : Clement Ripoll
Osivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine
Osivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine Combining OVX836 and GC FLU Combines Osivax’s proprietary OVX836 T-cell vaccine and technology with GC Biopharma’s marketed influenza vaccine and worldwide manufacturing expertise Positions Osivax as the global development lead for a differentiated next-generation influenza vaccine candidate Aims to deliver enhanced and …
Options XIII for the Control of Influenza
Washington, USA – Oral Presentation and Posters 30 August- 2 September, 2026 Isabel Leroux-Roels, Center for Vaccinology (CEVAC) – Ghent University Hospital to present Phase 2b field efficacy trial results as part of a presentation entitled “Phase 2b ASUNIVA topline results on efficacy safety and immunogenicity of OVX836 a broad-spectrum influenza A vaccine”. Alexandre …
Continuer la lecture « Options XIII for the Control of Influenza »